Combined therapy for diabetic macular edema.

Abstract

Diabetic macular edema (DME) is the main cause of visual impairment in diabetic patients. Macular edema within 1 disk diameter of the fovea is present in 9% of the diabetic population. The management of DME is complex and often multiple treatment approaches are needed. This review demonstrates the benefits of intravitreal triamcinolone, bevacizumab and ranibizumab as adjunctive therapy to macular laser treatment in DME. The published results indicate that intravitreal injections of these agents may have a beneficial effect on macular thickness and visual acuity, independent of the type of macular edema that is present. Therefore, pharmacotherapy could complement focal/grid laser photocoagulation in the management of DME. For this review, we performed a literature search and summarized recent findings regarding combined therapy for DME.

• Authors: Saba Al Rashaed, J Fernando Arevalo
• Journal: Middle East African journal of ophthalmology (Middle East Afr J Ophthalmol) 2013 Oct-Dec Vol. 20 Issue 4 Pg. 315-20 ISSN: 0975-1599 [Electronic] India
• PMID: 24339681 (Publication Type: Journal Article, Review)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Glucocorticoids
• Bevacizumab
• Triamcinolone Acetonide
• Ranibizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Combined Modality Therapy
• Diabetic Retinopathy (drug therapy, surgery, therapy)
• Glucocorticoids (therapeutic use)
• Humans
• Intravitreal Injections
• Laser Coagulation
• Macular Edema (drug therapy, surgery, therapy)
• Ranibizumab
• Triamcinolone Acetonide (therapeutic use)